{"hands_on_practices": [{"introduction": "Differentiating between the closely related pathogens *Shigella* and enteroinvasive *E. coli* (EIEC) is a significant challenge in clinical microbiology with implications for public health response. This practice will guide you through an integrative analysis, combining molecular data, classical phenotypic traits, and epidemiological context to make a definitive identification [@problem_id:4691840]. Mastering this approach is essential for accurately diagnosing and managing outbreaks of dysentery.", "problem": "A public health laboratory receives three isolates, labeled $A$, $B$, and $C$, from three temporally overlapping clusters of inflammatory diarrhea. Each isolate is assessed by quantitative Polymerase Chain Reaction (qPCR) targeting the invasion plasmid antigen H ($ipaH$) gene and a single-copy chromosomal housekeeping gene, malate dehydrogenase ($mdh$). The quantification cycle (Cq) values are measured in triplicate and averaged. All qPCR assays are run under the same conditions with verified near-$100\\%$ amplification efficiency for both targets, and the DNA inputs are normalized to the same genome-equivalent mass. The averaged Cq values are:\n\n- Isolate $A$: $Cq_{ipaH} = 18.0$, $Cq_{mdh} = 22.0$.\n- Isolate $B$: $Cq_{ipaH} = 24.5$, $Cq_{mdh} = 25.5$.\n- Isolate $C$: $Cq_{ipaH} = 20.5$, $Cq_{mdh} = 24.0$.\n\nIn parallel, each isolate is streaked on MacConkey agar and incubated at $37\\,^{\\circ}\\mathrm{C}$. Lactose fermentation phenotypes are recorded at $24$ hours and $48$ hours:\n\n- Isolate $A$: non-lactose fermenting at $24$ hours and still non-lactose fermenting at $48$ hours.\n- Isolate $B$: non-lactose fermenting at $24$ hours and lactose-fermenting (pink colonies) at $48$ hours.\n- Isolate $C$: non-lactose fermenting at $24$ hours and still non-lactose fermenting at $48$ hours.\n\nEpidemiologic context:\n\n- Cluster linked to isolate $A$: a daycare outbreak with high secondary household attack rates, person-to-person spread, and cases after minimal exposures consistent with a low infectious dose.\n- Cluster linked to isolate $B$: travel-associated cases in adults after consumption of large portions of street-vended food, no secondary transmission among close contacts, and illness generally milder, though with dysentery-like features.\n- Cluster linked to isolate $C$: a nursing home outbreak with efficient person-to-person transmission, several secondary cases among staff, and onset after brief exposures.\n\nUsing only fundamental, well-supported principles that (i) earlier qPCR Cq reflects more target template molecules in the input, (ii) Shigella species and enteroinvasive Escherichia coli (EIEC) both harbor the $ipaH$ target but typically differ in genome-wide $ipaH$ copy number per genome, (iii) Shigella species are classically non-lactose fermenters on MacConkey agar whereas EIEC strains are frequently late lactose fermenters, and (iv) Shigella species characteristically have a very low infectious dose with efficient person-to-person spread relative to EIEC, which more often requires higher-dose, foodborne exposures, determine which assignment best fits the integrated data.\n\nWhich option is most consistent with the combined genetic, phenotypic, and clinical-epidemiologic evidence?\n\nA. Isolates $A$ and $C$ are most consistent with Shigella species; isolate $B$ is most consistent with enteroinvasive Escherichia coli (EIEC).\n\nB. Isolate $A$ is most consistent with EIEC because non-lactose fermentation and high $ipaH$ copy number indicate acquisition of a Shiga toxin phage; isolates $B$ and $C$ are Shigella species.\n\nC. Isolate $B$ is most consistent with Shigella species because late lactose fermentation is typical of Shigella; isolates $A$ and $C$ are EIEC.\n\nD. All three isolates are most consistent with EIEC because they share colonic invasiveness and the $ipaH$ marker.", "solution": "The problem statement will be validated before proceeding to a solution.\n\n### Step 1: Extract Givens\n\n- **Isolates:** Three isolates labeled $A$, $B$, and $C$ from three inflammatory diarrhea clusters.\n- **Genetic Data (qPCR):**\n    - Targets: Invasion plasmid antigen H gene ($ipaH$) and malate dehydrogenase gene ($mdh$).\n    - $mdh$ is a single-copy chromosomal housekeeping gene.\n    - qPCR conditions: Same for all assays, near-$100\\%$ amplification efficiency, DNA inputs normalized to the same genome-equivalent mass.\n    - Averaged quantification cycle (Cq) values:\n        - Isolate $A$: $Cq_{ipaH} = 18.0$, $Cq_{mdh} = 22.0$.\n        - Isolate $B$: $Cq_{ipaH} = 24.5$, $Cq_{mdh} = 25.5$.\n        - Isolate $C$: $Cq_{ipaH} = 20.5$, $Cq_{mdh} = 24.0$.\n- **Phenotypic Data (MacConkey Agar):**\n    - Isolate $A$: Non-lactose fermenting at $24$ and $48$ hours.\n    - Isolate $B$: Non-lactose fermenting at $24$ hours, lactose-fermenting at $48$ hours (late lactose fermenter).\n    - Isolate $C$: Non-lactose fermenting at $24$ and $48$ hours.\n- **Epidemiologic Data:**\n    - Cluster $A$: Daycare, high secondary attack rates, person-to-person spread, low infectious dose.\n    - Cluster $B$: Travel-associated, adults, large food portions, no secondary transmission, milder illness.\n    - Cluster $C$: Nursing home, efficient person-to-person transmission, secondary cases, brief exposures.\n- **Guiding Principles:**\n    - (i) Earlier Cq reflects more target template molecules.\n    - (ii) *Shigella* species and enteroinvasive *Escherichia coli* (EIEC) both have the $ipaH$ target. *Shigella* species typically have a higher $ipaH$ copy number per genome than EIEC.\n    - (iii) *Shigella* species are classically non-lactose fermenters. EIEC strains are frequently late lactose fermenters.\n    - (iv) *Shigella* species have a very low infectious dose and efficient person-to-person spread. EIEC more often requires higher-dose, foodborne exposures.\n\n### Step 2: Validate Using Extracted Givens\n\n- **Scientific Grounding:** The problem is scientifically sound. It uses standard microbiological and molecular techniques (qPCR, culture on MacConkey agar) and established epidemiological characteristics to differentiate between *Shigella* species and EIEC. The choice of $ipaH$ as a shared virulence marker and $mdh$ as a single-copy chromosomal control is appropriate. The stated differences in $ipaH$ copy number, lactose fermentation, and infectious dose between *Shigella* and EIEC are well-documented facts in medical microbiology.\n- **Well-Posed:** The problem is well-posed. It provides sufficient, distinct data from three independent lines of evidence (genetic, phenotypic, epidemiologic) and a clear set of principles for their interpretation. The task is to find the most consistent assignment, which implies a unique best-fit solution exists.\n- **Objectivity:** The problem is stated objectively, using precise scientific terminology and quantitative data.\n- **Completeness and Consistency:** The problem is self-contained. All information needed to solve the problem is provided. There are no internal contradictions. The data from the different sources are designed to be complementary and convergent. The slight variation in $Cq_{mdh}$ values is a realistic feature of experimental data; the problem states the input was normalized, which is the key premise to trust. The calculation of the difference in Cq values ($\\Delta Cq$) is the standard method to internally normalize the virulence gene signal to the chromosomal signal for each isolate, making the comparison of copy numbers robust.\n\n### Step 3: Verdict and Action\n\nThe problem statement is valid. A solution will be derived.\n\n### Derivation of the Correct Answer\n\nThe task is to identify each isolate by integrating the provided genetic, phenotypic, and epidemiologic data according to the four given principles.\n\n**1. Analysis of Genetic Data (qPCR)**\n\nAccording to principles (i) and (ii), the relative copy number of the $ipaH$ gene per genome can be estimated by comparing its Cq value to that of the single-copy housekeeping gene $mdh$. For a qPCR with amplification efficiency ($E$) near $100\\%$, $E \\approx 2$. The initial number of template copies ($N_0$) is related to the Cq value by $N_0 \\propto E^{-Cq}$.\n\nThe ratio of initial template molecules for $ipaH$ and $mdh$ is given by:\n$$ \\frac{N_{0, ipaH}}{N_{0, mdh}} \\approx \\frac{2^{-Cq_{ipaH}}}{2^{-Cq_{mdh}}} = 2^{Cq_{mdh} - Cq_{ipaH}} = 2^{\\Delta Cq} $$\nSince $mdh$ is a single-copy gene, this ratio is a direct estimate of the $ipaH$ copy number per genome. A higher $\\Delta Cq$ value signifies a higher $ipaH$ copy number. According to principle (ii), *Shigella* species are expected to have a higher $\\Delta Cq$ than EIEC.\n\nLet's calculate $\\Delta Cq$ for each isolate:\n- **Isolate A:** $\\Delta Cq_A = Cq_{mdh} - Cq_{ipaH} = 22.0 - 18.0 = 4.0$. This implies an $ipaH$ copy number of approximately $2^{4.0} = 16$. This is a high copy number, strongly suggesting **Shigella**.\n- **Isolate B:** $\\Delta Cq_B = Cq_{mdh} - Cq_{ipaH} = 25.5 - 24.5 = 1.0$. This implies an $ipaH$ copy number of approximately $2^{1.0} = 2$. This is a low copy number, strongly suggesting **EIEC**. (Often one copy on the plasmid and one cryptic chromosomal copy).\n- **Isolate C:** $\\Delta Cq_C = Cq_{mdh} - Cq_{ipaH} = 24.0 - 20.5 = 3.5$. This implies an $ipaH$ copy number of approximately $2^{3.5} \\approx 11.3$. This is a high copy number, strongly suggesting **Shigella**.\n\n**2. Analysis of Phenotypic Data (Lactose Fermentation)**\n\nAccording to principle (iii):\n- *Shigella* species are classically non-lactose fermenters.\n- EIEC strains are frequently late lactose fermenters.\n\n- **Isolate A:** Non-lactose fermenter. This is consistent with **Shigella**.\n- **Isolate B:** Late lactose fermenter. This is consistent with **EIEC**.\n- **Isolate C:** Non-lactose fermenter. This is consistent with **Shigella**.\n\n**3. Analysis of Epidemiologic Data**\n\nAccording to principle (iv):\n- *Shigella* species cause outbreaks characterized by a low infectious dose and efficient person-to-person transmission.\n- EIEC-associated illness typically requires a higher infectious dose (e.g., from contaminated food) and shows limited secondary spread.\n\n- **Cluster A:** Daycare setting, high secondary attack rates, and person-to-person spread imply a low infectious dose. This epidemiology is characteristic of **Shigella**.\n- **Cluster B:** Travel-associated cases from street-vended food (implying a potentially large inoculum), with no secondary transmission, suggest a higher infectious dose pathogen. This is characteristic of **EIEC**.\n- **Cluster C:** Nursing home outbreak with efficient person-to-person transmission, even from brief exposures, points to a low infectious dose pathogen. This is characteristic of **Shigella**.\n\n**4. Synthesis**\n\nThe evidence from all three sources converges consistently for each isolate:\n\n| Isolate | Genetic Evidence ($\\Delta Cq$) | Phenotypic Evidence (Lactose) | Epidemiologic Evidence | Conclusion |\n| :--- | :--- | :--- | :--- | :--- |\n| **A** | High copy number ($4.0$) | Non-fermenter | Low dose, person-to-person | **Shigella** |\n| **B** | Low copy number ($1.0$) | Late fermenter | High dose, foodborne | **EIEC** |\n| **C** | High copy number ($3.5$) | Non-fermenter | Low dose, person-to-person | **Shigella** |\n\nTherefore, the most consistent assignment is that isolates $A$ and $C$ are *Shigella* species, and isolate $B$ is EIEC.\n\n### Evaluation of Options\n\n**A. Isolates $A$ and $C$ are most consistent with Shigella species; isolate $B$ is most consistent with enteroinvasive Escherichia coli (EIEC).**\nThis statement perfectly matches the synthesis of the genetic, phenotypic, and epidemiologic data. The high $ipaH$ copy number, non-lactose fermentation, and low-infectious-dose epidemiology of isolates $A$ and $C$ are all hallmarks of *Shigella*. The low $ipaH$ copy number, late lactose fermentation, and high-infectious-dose epidemiology of isolate $B$ are all hallmarks of EIEC.\n**Verdict: Correct.**\n\n**B. Isolate $A$ is most consistent with EIEC because non-lactose fermentation and high $ipaH$ copy number indicate acquisition of a Shiga toxin phage; isolates $B$ and $C$ are Shigella species.**\nThis statement is incorrect on multiple grounds. First, it misidentifies the isolates; the evidence points to $A$ being *Shigella*, not EIEC. Second, the reasoning is biologically flawed. A high $ipaH$ copy number is characteristic of *Shigella*, not EIEC (violates principle ii). Third, Shiga toxin phages carry genes for Shiga toxin (*stx*), not $ipaH$, and their acquisition has no bearing on $ipaH$ copy number or lactose fermentation status.\n**Verdict: Incorrect.**\n\n**C. Isolate $B$ is most consistent with Shigella species because late lactose fermentation is typical of Shigella; isolates $A$ and $C$ are EIEC.**\nThis statement is incorrect. It reverses the correct identifications. The reasoning is also contrary to the provided principles. While *Shigella sonnei* is a known late lactose fermenter, principle (iii) explicitly directs us to associate late lactose fermentation with EIEC for the purpose of this differentiation exercise. Furthermore, the genetic and epidemiological data for isolate $B$ both strongly point to EIEC, not *Shigella*.\n**Verdict: Incorrect.**\n\n**D. All three isolates are most consistent with EIEC because they share colonic invasiveness and the $ipaH$ marker.**\nThis statement is a gross oversimplification that ignores the rich differential data provided in the problem. While it is true that both *Shigella* and EIEC are invasive and possess the $ipaH$ gene, the problem is specifically about *differentiating* them based on copy number, phenotype, and epidemiology. This option fails to perform any differentiation and thus does not represent the \"most consistent\" explanation of the detailed data.\n**Verdict: Incorrect.**", "answer": "$$\\boxed{A}$$", "id": "4691840"}, {"introduction": "A hallmark of *Shigella* is its high transmissibility and low infectious dose, which often lead to explosive outbreaks. This exercise introduces a core epidemiological tool, the secondary attack rate (SAR), to quantify this spread within a defined population [@problem_id:4676684]. By calculating the SAR in a household setting, you will gain a practical understanding of how public health officials measure and communicate the risk of infection.", "problem": "In a household cluster of bacillary dysentery caused by Shigella species, an index case is identified. Over the subsequent incubation period, $3$ of $10$ susceptible household contacts develop shigellosis attributable to fecal–oral transmission from the index case. Calculate the secondary attack rate for this household cluster. Express the final value as a decimal number (unitless) and round to three significant figures.", "solution": "The problem requires the calculation of the secondary attack rate for a household cluster of bacillary dysentery. Before proceeding, the problem statement is validated.\n\n**Problem Validation**\n\n**Step 1: Extract Givens**\n- Disease: Bacillary dysentery caused by *Shigella* species.\n- Setting: A household cluster.\n- Index case: $1$ identified.\n- Population at risk: $10$ susceptible household contacts.\n- New cases among contacts: $3$.\n- Timeframe: Over the subsequent incubation period.\n- Task: Calculate the secondary attack rate.\n- Required format: Decimal number rounded to three significant figures.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded, well-posed, and objective. The scenario described is a classic epidemiological investigation of an infectious disease outbreak in a small community. The concepts of an index case, susceptible contacts, and secondary attack rate are standard and well-defined in epidemiology and medical microbiology. The data provided ($3$ cases out of $10$ contacts) are sufficient and consistent for calculating the requested measure. There are no violations of scientific principles, ambiguities, or missing information. The problem is valid.\n\n**Solution**\n\nThe secondary attack rate (SAR) is an epidemiological metric that measures the frequency of new cases of a disease among the susceptible contacts of a known case. It quantifies the risk of transmission from a primary case to their close contacts. The formula for the secondary attack rate is:\n$$ \\text{SAR} = \\frac{\\text{Number of new cases among susceptible contacts}}{\\text{Total number of susceptible contacts}} $$\nThis rate is typically calculated for a period corresponding to one incubation period of the disease, which is consistent with the problem statement.\n\nFrom the givens extracted from the problem statement, we identify the following values:\n- The number of new cases among susceptible contacts, which we can denote as $N_{\\text{cases}}$, is $3$.\n- The total number of susceptible household contacts, which we can denote as $N_{\\text{contacts}}$, is $10$.\n\nThe index case is the source of the infection and is, by definition, not part of the population at risk for secondary infection. The denominator of the SAR correctly includes only those who were susceptible to begin with. The problem correctly specifies the population at risk as the \"$10$ susceptible household contacts\".\n\nSubstituting the given values into the formula for the secondary attack rate:\n$$ \\text{SAR} = \\frac{N_{\\text{cases}}}{N_{\\text{contacts}}} = \\frac{3}{10} $$\nPerforming the division gives the rate as a decimal:\n$$ \\text{SAR} = 0.3 $$\nThe problem requires this value to be expressed as a decimal number rounded to three significant figures. To represent $0.3$ with three significant figures, we must add two trailing zeros. Thus, the value becomes $0.300$. These trailing zeros after the decimal point are significant and indicate the specified level of precision. The secondary attack rate is a proportion and is therefore a unitless quantity.", "answer": "$$\\boxed{0.300}$$", "id": "4676684"}, {"introduction": "Successful antimicrobial therapy depends on achieving drug exposures sufficient to kill the target pathogen at the site of infection. This exercise bridges the gap between laboratory susceptibility testing and clinical practice by applying pharmacokinetic/pharmacodynamic (PK/PD) modeling to the treatment of *Shigella* colitis [@problem_id:4676637]. You will calculate the maximum minimum inhibitory concentration (MIC) that a standard ciprofloxacin regimen can effectively treat, providing a quantitative basis for clinical decision-making.", "problem": "A patient with bacillary dysentery due to Shigella flexneri presents with acute colitis. For fluoroquinolones, a well-established pharmacokinetic/pharmacodynamic (PK/PD) principle is that antibacterial efficacy against Gram-negative bacilli is primarily driven by the ratio of the unbound (free) plasma area under the concentration–time curve over a $24$-hour interval to the minimum inhibitory concentration, denoted $X = f\\mathrm{AUC}_{0\\text{–}24}/\\mathrm{MIC}$. Assume the exposure–response for net bacterial burden change over $24$ hours in colonic tissue can be modeled by a maximal effect relationship:\n\n$$\nE = E_{\\max}\\,\\frac{X}{EC_{50} + X},\n$$\n\nwhere $E$ is the net reduction in $\\log_{10}$ colony-forming units (CFU) over $24$ hours, $E_{\\max}$ is the maximal achievable $\\log_{10}$ CFU reduction, and $EC_{50}$ is the value of $X$ that produces one-half of $E_{\\max}$. Use the following scientifically grounded values for Shigella colitis treated with ciprofloxacin:\n- $E_{\\max} = 4.0$ $\\log_{10}$ CFU reduction,\n- $EC_{50} = 60$,\n- bacteriological cure requires at least $E_{\\text{cure}} = 2.5$ $\\log_{10}$ CFU reduction over $24$ hours.\n\nCiprofloxacin pharmacokinetics in adults at steady state can be approximated by linear one-compartment behavior with the following parameters:\n- standard outpatient regimen: $500$ mg orally every $12$ hours (total daily dose $= 1000$ mg),\n- absolute oral bioavailability $F = 0.70$,\n- systemic clearance $\\mathrm{CL} = 20$ L/h,\n- unbound fraction in plasma $f_{u} = 0.70$.\n\nAssume that colonic interstitial concentrations relevant for Shigella exposure are reflected by unbound plasma concentrations, and that the $24$-hour area under the curve at steady state is given by $ \\mathrm{AUC}_{0\\text{–}24} = \\dfrac{F \\cdot \\text{daily dose}}{\\mathrm{CL}} $, with the free exposure $f\\mathrm{AUC}_{0\\text{–}24} = f_{u} \\cdot \\mathrm{AUC}_{0\\text{–}24}$.\n\nStarting from these definitions and relationships (do not assume any unstated shortcuts), first determine the minimum target $X^{\\ast}$ required to achieve $E_{\\text{cure}}$ from the exposure–response model. Then, using the standard dosing and pharmacokinetics above, compute the maximum $\\mathrm{MIC}$ (in mg/L) for which the regimen attains $X^{\\ast}$ and is therefore predicted to achieve bacteriological cure. Express your final answer as a single number in mg/L, rounded to three significant figures.", "solution": "The user wants me to solve a pharmacokinetics/pharmacodynamics problem.\n\n### Step 1: Extract Givens\nThe problem provides the following data, definitions, and relationships:\n- The pharmacokinetic/pharmacodynamic (PK/PD) index is $X = f\\mathrm{AUC}_{0\\text{–}24}/\\mathrm{MIC}$.\n- The exposure–response model is an $E_{\\max}$ relationship: $E = E_{\\max}\\,\\frac{X}{EC_{50} + X}$.\n- $E$ is the net reduction in $\\log_{10}$ colony-forming units (CFU) over $24$ hours.\n- $E_{\\max} = 4.0$ $\\log_{10}$ CFU reduction.\n- $EC_{50} = 60$.\n- The target for bacteriological cure is $E_{\\text{cure}} = 2.5$ $\\log_{10}$ CFU reduction.\n- The ciprofloxacin regimen is $500$ mg orally every $12$ hours, making the total daily dose $1000$ mg.\n- Absolute oral bioavailability $F = 0.70$.\n- Systemic clearance $\\mathrm{CL} = 20$ L/h.\n- Unbound fraction in plasma $f_{u} = 0.70$.\n- The formula for the a $24$-hour area under the curve at steady state is given as $\\mathrm{AUC}_{0\\text{–}24} = \\dfrac{F \\cdot \\text{daily dose}}{\\mathrm{CL}}$.\n- The free drug exposure is $f\\mathrm{AUC}_{0\\text{–}24} = f_{u} \\cdot \\mathrm{AUC}_{0\\text{–}24}$.\n- The final answer for the maximum MIC should be in mg/L and rounded to three significant figures.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is evaluated against the validation criteria:\n- **Scientifically Grounded**: The problem uses standard, well-established models in pharmacology and microbiology. The $E_{\\max}$ model is a fundamental concept in dose-response relationships. The PK/PD index $f\\mathrm{AUC}/\\mathrm{MIC}$ is the accepted driver of efficacy for fluoroquinolones. The pharmacokinetic equations and parameters for ciprofloxacin are standard and realistic. The problem is scientifically sound.\n- **Well-Posed**: The problem is clearly stated and provides all necessary equations and parameter values to calculate a unique numerical answer. The question is structured logically, asking for an intermediate value ($X^{\\ast}$) and then a final value ($\\mathrm{MIC}_{\\max}$).\n- **Objective**: The problem uses precise, quantitative language and is free of subjective or ambiguous terminology.\n- **Completeness and Consistency**: All required data are provided. No information is missing or contradictory. The units are implicitly consistent: if $\\mathrm{AUC}$ is in mg·h/L and $\\mathrm{MIC}$ is in mg/L, then $X$ has units of hours, which is consistent with $EC_{50}$ being a value of $X$.\n- **No other flaws are identified.**\n\n### Step 3: Verdict and Action\nThe problem is valid. A full solution will be provided.\n\nThe solution proceeds in two main parts as outlined by the problem statement. First, we determine the target PK/PD index, $X^{\\ast}$, required for bacteriological cure. Second, we calculate the drug exposure for the given regimen and use it along with $X^{\\ast}$ to find the maximum allowable Minimum Inhibitory Concentration ($\\mathrm{MIC}$).\n\n**Part 1: Determine the target PK/PD index, $X^{\\ast}$**\n\nThe exposure-response relationship is given by the $E_{\\max}$ model:\n$$\nE = E_{\\max}\\,\\frac{X}{EC_{50} + X}\n$$\nWe need to find the value of the index $X$, denoted as $X^{\\ast}$, that corresponds to the effect required for cure, $E_{\\text{cure}}$. We set $E = E_{\\text{cure}}$ and solve for $X=X^{\\ast}$:\n$$\nE_{\\text{cure}} = E_{\\max}\\,\\frac{X^{\\ast}}{EC_{50} + X^{\\ast}}\n$$\nSubstituting the given values $E_{\\text{cure}} = 2.5$, $E_{\\max} = 4.0$, and $EC_{50} = 60$:\n$$\n2.5 = 4.0 \\cdot \\frac{X^{\\ast}}{60 + X^{\\ast}}\n$$\nTo solve for $X^{\\ast}$, we first rearrange the equation:\n$$\n\\frac{2.5}{4.0} = \\frac{X^{\\ast}}{60 + X^{\\ast}}\n$$\n$$\n0.625 = \\frac{X^{\\ast}}{60 + X^{\\ast}}\n$$\n$$\n0.625 \\cdot (60 + X^{\\ast}) = X^{\\ast}\n$$\n$$\n(0.625 \\cdot 60) + 0.625 \\cdot X^{\\ast} = X^{\\ast}\n$$\n$$\n37.5 + 0.625 X^{\\ast} = X^{\\ast}\n$$\n$$\n37.5 = X^{\\ast} - 0.625 X^{\\ast}\n$$\n$$\n37.5 = (1 - 0.625) X^{\\ast}\n$$\n$$\n37.5 = 0.375 X^{\\ast}\n$$\n$$\nX^{\\ast} = \\frac{37.5}{0.375} = 100\n$$\nThus, the minimum target value for the PK/PD index to achieve bacteriological cure is $X^{\\ast} = 100$. Note that since $\\mathrm{AUC}$ is in units of (concentration $\\times$ time) and $\\mathrm{MIC}$ is in units of concentration, the index $X$ has units of time (hours). So, $X^{\\ast} = 100$ h.\n\n**Part 2: Compute the maximum MIC for the regimen**\n\nThe PK/PD index is defined as $X = \\frac{f\\mathrm{AUC}_{0\\text{–}24}}{\\mathrm{MIC}}$. To achieve the target $X^{\\ast}$, the following condition must be met:\n$$\n\\frac{f\\mathrm{AUC}_{0\\text{–}24}}{\\mathrm{MIC}} \\geq X^{\\ast}\n$$\nThis implies that for a given drug exposure, there is a maximum MIC, which we will call $\\mathrm{MIC}_{\\max}$, for which the regimen is effective:\n$$\n\\mathrm{MIC}_{\\max} = \\frac{f\\mathrm{AUC}_{0\\text{–}24}}{X^{\\ast}}\n$$\nFirst, we calculate the free drug exposure over $24$ hours, $f\\mathrm{AUC}_{0\\text{–}24}$. We are given the relationships:\n$$\n\\mathrm{AUC}_{0\\text{–}24} = \\frac{F \\cdot \\text{daily dose}}{\\mathrm{CL}} \\quad \\text{and} \\quad f\\mathrm{AUC}_{0\\text{–}24} = f_{u} \\cdot \\mathrm{AUC}_{0\\text{–}24}\n$$\nCombining these, we get:\n$$\nf\\mathrm{AUC}_{0\\text{–}24} = f_u \\cdot \\frac{F \\cdot \\text{daily dose}}{\\mathrm{CL}}\n$$\nNow, we substitute the provided pharmacokinetic parameters: total daily dose $= 1000$ mg, $F = 0.70$, $\\mathrm{CL} = 20$ L/h, and $f_{u} = 0.70$.\n$$\nf\\mathrm{AUC}_{0\\text{–}24} = 0.70 \\cdot \\frac{0.70 \\cdot 1000 \\, \\text{mg}}{20 \\, \\text{L/h}}\n$$\n$$\nf\\mathrm{AUC}_{0\\text{–}24} = 0.70 \\cdot \\frac{700 \\, \\text{mg}}{20 \\, \\text{L/h}}\n$$\n$$\nf\\mathrm{AUC}_{0\\text{–}24} = 0.70 \\cdot (35 \\, \\text{mg}\\cdot\\text{h/L})\n$$\n$$\nf\\mathrm{AUC}_{0\\text{–}24} = 24.5 \\, \\text{mg}\\cdot\\text{h/L}\n$$\nNow we can compute the maximum MIC by substituting the values for $f\\mathrm{AUC}_{0\\text{–}24}$ and $X^{\\ast}$:\n$$\n\\mathrm{MIC}_{\\max} = \\frac{24.5 \\, \\text{mg}\\cdot\\text{h/L}}{100 \\, \\text{h}}\n$$\n$$\n\\mathrm{MIC}_{\\max} = 0.245 \\, \\text{mg/L}\n$$\nThe problem asks for the answer to be rounded to three significant figures. The calculated value of $0.245$ already has three significant figures. Therefore, the maximum MIC for which the regimen is predicted to achieve bacteriological cure is $0.245$ mg/L.", "answer": "$$\n\\boxed{0.245}\n$$", "id": "4676637"}]}